Structured evidence table for Matcha Blood Pressure Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Matcha Blood Pressure Randomized Trial | Polyphenols strengthen the intestinal barrier and reduce endotoxemia; cocoa bean shell extracts protected against oxysterol‐induced intestinal damage and improved gut microbiota composition in preclinical models (Alia et al. ). | 3 | Akif Adnan (2026) | Dietary Polyphenols in Non‐Communicable Chronic Diseases: Neuro–Enteric Mechanisms, Multi‐Omics Biomarkers and Translational Opportunities |
| Matcha Blood Pressure Randomized Trial | While many epidemiological studies correlate polyphenol‐rich diets (e.g., Mediterranean diet) with reduced NCCD risk, causality is uncertain due to confounding and measurement error. | 3 | Akif Adnan (2026) | Dietary Polyphenols in Non‐Communicable Chronic Diseases: Neuro–Enteric Mechanisms, Multi‐Omics Biomarkers and Translational Opportunities |
| Matcha Blood Pressure Randomized Trial | Controlled trials provide more robust evidence but vary widely in doses, formulations, populations and endpoints. | 3 | Akif Adnan (2026) | Dietary Polyphenols in Non‐Communicable Chronic Diseases: Neuro–Enteric Mechanisms, Multi‐Omics Biomarkers and Translational Opportunities |
| Matcha Blood Pressure Randomized Trial | AMP BBB CNS COMT COSMOS CRP (hs‐CRP) CSF EGCG ENB‐2 (ENB) ENS EVOO FMD GAD‐7 (GAD) GM‐CSF (GM) HDL HOMA‐IR (HOMA) IBS IL IR LDL LPS MCI MMSE NADPH NCCD (NCCDs) PHGG PHQ‐9 (PHQ) PSQI PWV RBANS RCT SCFA SD TNF (TNF‐α) 2024 Non‐communicable chronic diseases account for the majority of morbidity and mortality worldwide. | 3 | Akif Adnan (2026) | Dietary Polyphenols in Non‐Communicable Chronic Diseases: Neuro–Enteric Mechanisms, Multi‐Omics Biomarkers and Translational Opportunities |
| Matcha Blood Pressure Randomized Trial | In contrast, the t½ (h) of nadolol increased significantly from 4.0 ± 1.6 in the control group to 7.7 ± 4.2 (p = .039) in the matcha multiple-dose group. | 4 | Mashaqbeh ET (2026) | Effects of matcha green tea on the pharmacokinetics of nadolol in rats. |
| Matcha Blood Pressure Randomized Trial | Itraconazole co-administration significantly increased systemic exposure (AUC) of nadolol (p = .009), confirming the validity of the animal model. | 4 | Mashaqbeh ET (2026) | Effects of matcha green tea on the pharmacokinetics of nadolol in rats. |
| Matcha Blood Pressure Randomized Trial | Single and multiple oral doses of matcha green tea had negligible effects on most pharmacokinetic parameters of nadolol, except for an increased half-life in the multiple-dose group. | 4 | Mashaqbeh ET (2026) | Effects of matcha green tea on the pharmacokinetics of nadolol in rats. |
| Matcha Blood Pressure Randomized Trial | The concurrent use of herbal dietary supplements with prescription medications raises safety concerns due to the potential for clinically significant interactions. | 4 | Mashaqbeh ET (2026) | Effects of matcha green tea on the pharmacokinetics of nadolol in rats. |
Source documents